ADMA Biologics, Inc.

ADMA Biologics, Inc. Earnings Recaps

ADMA Health Care 3 recaps
Next earnings: February 24, 2027 (estimated) · full calendar
Q3 2026 Nov 8, 2026

ADMA shares rose 26.0% after earnings, as investors responded to 31% year-over-year ASCENIV growth, 71% corporate gross margin and substantial earnings growth. The quarter also showed continued pressure on BIVIGAM revenue, while management pointed to early signs of stabilization in end-user utilization.

Key takeaways
  • ASCENIV revenue was $124.7 million, up 31% year over year and 21% sequentially; management cited broader physician adoption, new patient starts and higher end-user utilization.
  • Total revenue increased 13% sequentially to $141.1 million, and corporate gross margin was 71%.
  • BIVIGAM revenue fell to $15.4 million from $19.4 million in the second quarter amid pricing and competitive pressure; management said underlying utilization showed signs of stabilization entering the fourth quarter.
  • ADMA repurchased 16.5 million shares through September 30, about 6.3% of shares outstanding at year-end 2025, and remained on track for its target of at least $200 million in 2026 repurchases.
  • Management said ASCENIV growth in secondary immunodeficiency patients has been moderate so far, despite viewing that population as a potential additional growth opportunity.
Q1 2026 May 8, 2026

ADMA Biologics shares dropped 18.9% following earnings due to continued top-line pressures on BIVIGAM amid intensified competitive dynamics and disruptive distributor ordering patterns, which overshadowed strong ASCENIV demand and margin expansion.

Key takeaways
  • Total revenue was essentially flat, weighed down by BIVIGAM’s challenges related to aggressive competitor discounting and inventory recalibration at distributors.
  • ASCENIV revenue grew approximately 28% year-over-year, driven by record patient starts, prescriber adoption, and strong patient adherence.
  • Corporate gross margins expanded to 71%, reflecting targeted expense reductions and operational efficiencies.
  • Adjusted net income increased 22% year-over-year, supported by margin improvement and $58 million in operating cash flow.
  • Management described the adverse distributor ordering variability as transitory and industry-wide, expecting demand normalization in Q2, but the market remains unconvinced given near-term revenue headwinds.
Q3 2025 Nov 6, 2025

ADMA Biologics reported a strong third quarter of 2025, with total revenue reaching $134.2 million, showcasing solid sequential and year-over-year growth driven by record utilization of ASCENIV and operational advancements.

Key takeaways
  • Total revenue increased 10% quarter-over-quarter and 12% year-over-year to $134.2 million.
  • GAAP net income rose to $36.4 million, a 6% increase from the previous quarter and 1% year-over-year.
  • Adjusted EBITDA grew by 16% quarter-over-quarter and 29% year-over-year to $58.7 million, indicating enhanced operational leverage.
  • ASCENIV observed significant patient-driven demand, with promising payer negotiations expected to improve reimbursement access in 2026.
  • Operational advancements, including FDA regulatory approval for yield-enhanced production, are projected to enhance gross margins substantially starting Q4 2025.